Weight-loss patients may soon have access to more GLP-1 treatments as Eli Lilly confirmed the local regulator was evaluating its new oral obesity drug, orforglipron, which a recent study showed was more effective than the oral equivalent of popular drug Wegovy.
Orforglipron is under review by the Food and Drug Administration in the US, and the company’s CFO, Lucas Montarce, told a healthcare conference in Boston earlier this week he expected the pill to be available in America as early as the second quarter of this year.
